Romlusevimab (BRII-198) is a neutralizing recombinant human IgG1 monoclonal antibody against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Romlusevimab and Amubarvimab bind to distinct epitopes of the SARS-CoV-2 spike protein[1].
Romlusevimab has an additive effect when combined with Amubarvimab[1].
Romlusevimab (10 mg/kg, ip, single) in combination with Amubarvimab protects animals from Omicron infection in a mouse model of SARS-CoV-2 infection[1].
References:
[1]. Hoy SM. Amubarvimab/Romlusevimab: First Approval. Drugs. 2022 Aug;82(12):1327-1331.
[2]. Ji Y, et al. Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2. Front Immunol. 2022 Sep 14;13:980435.
















